Artesunate plus sulfamethoxypyrazine/pyrimethamine for the treatment of cutaneous leishmaniasis: a double-blind, placebo-controlled clinical trial.
Adam
Ishag
I
Hagelnur
Amel A
AA
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use; D000077332:Artesunate; D002648:Child; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D008875:Middle Aged; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use; D013415:Sulfalene / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000981:Antiprotozoal Agents; D037621:Artemisinins; D000077332:Artesunate; D013415:Sulfalene; D011739:Pyrimethamine